tbuckley/cabot-search huggingface dataset:
TEMPORAL TRENDS AND OUTCOMES OF EMERGENT CORONARY ARTERY BYPASS GRAFT SURGERY FOR ST-SEGEMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Sahil Agrawal, Manyoo Agarwal, Lohit Garg, Aakash Garg, Abhishek Sharma, Nirmanmoh Bhatia, Divyanshu Mohananey, Amitoj Singh, Peter Puleo, John Kostis, Jamshid Shirani
Journal: Journal of the American College of Cardiology (2017)
High Levels of Fecal Calprotectin and alpha1-Antitrypsin At Diagnosis of Acute Gastro-Intestinal Graft-Versus-Host Disease Are Correlated with Severity and Response to Corticosteroids
Authors: Paula Rodriguez-Otero, Raphael Porcher, Régis Peffault de Latour, Margarita Contreras, Alienor Xhaard, Yoram Bouhnik, Annalisa Andreoli, Patricia Ribaud, Nathalie Kapel, Gerard Socie, Marie Robin
Journal: Blood (2011)
STANDARD VERSUS LOW-DOSE HEPARIN USE ON ACCESS-RELATED COMPLICATIONS AFTER CORONARY ANGIOGRAPHY THROUGH RADIAL ACCESS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Khagendra Dahal, Sharan Sharma, Jagan Beedupalli, Juyong Lee, Enrique Jimenez, Kalgi Modi, Neeraj Tandon
Journal: Journal of the American College of Cardiology (2017)
BODY MASS INDEX AND ACUTE AORTIC DISSECTION
Authors: Jordan Jabara, Santi Trimarchi, Alan Braverman, Marco Di Eusanio, Truls Myrmel, Marek Ehrlich, Hans-Henning Eckstein, Maral Ouzounian, Gilbert Upchurch, Ali Khoynezhad, Bradley Taylor, Daniel Montgomery, Christoph Nienaber, Kim Eagle, Eric Isselbacher, Himanshu Patel
Journal: Journal of the American College of Cardiology (2017)
EFICACIA Y SEGURIDAD DEL DRENAJE POR CPRE CON PRÓTESIS BILIARES PARA EL TRATAMIENTO ENDOSCÓPICO DE ICTERICIA OBSTRUCTIVA SECUNDARIA A METÁSTASIS HEPÁTICAS
Authors: M Martinez Guillen, C Guarner Argente, C Gomez Oliva, C Martin Maria Del Mar, J Colan Hernandez, C Villanueva Sanchez, S Sainz Saez-Sanchez, C Guarner Aguilar
Journal: Endoscopy (2015)

Introducción: La ictericia obstructiva secundaria a metástasis hepáticas aumenta la morbilidad en pacientes oncológicos. La indicación de drenaje por CPRE es poco frecuente, siendo una posibilidad en pacientes con vías intrahepáticas dilatadas, aunque su eficacia es dudosa.
In Pediatric Mature B-Cell Non Hodgkin Lymphoma (NHL), Complex Karyotype or del(13q) Are Linked Prognostic Factors in Burkitt Lymphoma (BL) While 8q24/c-myc Rearrangement Is Associated with a Strong Adverse Effect in Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Hélène A. Poirel, Nyla A. Heerema, John Swansbury, Anne Aupérin, Erika Launay, Warren G. Sanger, Polly Talley, Martine Raphael, Sherrie Perkins, Keith McCarthy, Richard Sposto, Claire Weston, Mary Gerrard, Mitch S. Cairo, Alain Bernheim, Catherine Patte
Journal: Blood (2005)
Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD)
Authors: A. Yver, R. Cohen, D. Williams, M. Von Mehren
Journal: Journal of Clinical Oncology (2006)

9568 Background: T (ET-743) is a first-in-class compound that binds the minor groove of DNA. T has activity in soft tissue sarcoma and ovarian cancers with predictable, transient, non-cumulative and reversible hepatic toxicity, compatible with long term treatment. The combination of T and doxorubicin had preclinical synergistic activity. This study tested T + PLD in advanced malignancies. Methods: Eligibility included normal cardiac and liver functions, prior doxorubicin exposure &lt;250 mg/m 2 . PLD 30 mg/m 2 was administered iv 1-hour followed by 1 of 6 T doses (0.4 -1.3 mg/m 2 ) iv 3 hours q 21 days. In select subjects (4 at pre/post cycle 1, 4 under long term treatment -cycle 14, 20, 30 and 30), liver biopsies were done with expert independent review. Results: Six dose levels of T were evaluated in 30 subjects. The DLTs were 1 grade 3 AST and 2 grade 4 ALT elevations seen at T 1.3 mg/m 2 . Grade 3–4 toxicities were: ALT elevation (4%), neutropenia (3%), hand-foot syndrome (2%), AST elevation (1%) and nausea/vomiting (1%). Liver biopsies were obtained from 8 subjects (1 in 0.6, 7 in 1.1 mg/m 2 T dose cohorts), age 45–78 years, with sarcoma (4), and ovarian (2), uterine (1), and head and neck (1) cancers. T and PLD mean drug exposure for these subjects was 15 (2–36) and 12 (2–24) cycles, respectively. Mean total doses for T and PLD were 23.2 (3.4–39) and 597 (94–1296) mg, respectively. Findings included NASH (nonalcoholic steatohepatitis), severity ranging from minimal steatosis to moderate steatosis with fibrosis. Pre/post treatment biopsies showed no change in NASH pre/post in 3 cases, one subject had minimal post-treatment steatosis. No mitochondrial abnormalities or stellate cell activation were observed. Review concluded no evidence of persistent liver pathological abnormalities attributable to T. Conclusions: The MTD of T is 1.1 mg/m 2 with 30 mg/m 2 PLD q 21 days, and is well tolerated when both drugs are administered at near full therapeutic doses for prolonged periods. Liver biopsies did not demonstrate clinically relevant hepatic tissue toxicity. As reported previously, this is an active regimen which is being further evaluated in an ongoing Phase III study in relapsed ovarian cancer. [Table: see text]
Utilization of <i>BRCA1/BRCA2</i> testing in Veterans Health Administration.
Authors: Danielle Chun, Julie Ann Lynch, Scott L. DuVall, Kelly Kristin Filipski, Michael J. Kelley, Brygida Berse, Vickie Venne
Journal: Journal of Clinical Oncology (2015)

e17510 Background: About 10% of Veterans seen in VA facilities are female, some of whom are diagnosed with breast cancer. In 2012, NCCN guidelines for BRCA1/BRCA2 testing criteria included offering genetic testing to women diagnosed ≤ age 45, and ≤ age 50 if there was a family history or an additional primary.With the introduction of multi-gene panels to evaluate for a genetic etiology of a breast cancer diagnosis, we sought to assess baseline use of breast cancer genetic testing in an environment that has historically focused on cancers more common in males. Methods: The VA Cancer registry (VACCR) was used to identify Veterans diagnosed with breast cancer aged 50 years or younger for years 2011-2012. Data on patients receiving BRCA testing were provided by Myriad Genetics and linked to the VACCR dataset. We examined patient and clinical characteristics to determine predictors of BRCAtesting. Logistic regression was performed to obtain odds ratios (ORs) and 95% confidence intervals (CIs). Results: 250 Veteran patients aged 50 years or younger were identified from 75 VA facilities. Of those, 66 (26%) received BRCA testing. The mean age of those tested was 42 years (range: 23-50 years). A significant decreased likelihood in testing was shown with every increasing year of age (βcoeff: -0.13; CI: -0.19, -0.07, p < 0.001.) No statistically significant differences in receiving tests were observed between whites (28%) and blacks (25%). Among those who had family history of any reportable cancer, 30% received BRCA testing compared to 19% who did not have a documented family history; family history was not a significant predictor of testing. Conclusions: In the VA health care system, 26% of the total patients diagnosed with breast cancer received BRCA1/2 testing. Previous studies demonstrated racial disparities in BRCA1/2 testing utilization. However, our findings show no differences in utilization across races. The documentation of family history, another test criterion, varied significantly. Analyses of family history documentation, especially for Veterans between age 40 and 50, as well as differences in regional and site of care, are ongoing and will be presented at the meeting.
A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease
Authors: J. R. Berenson, O. Yellin, R. Mapes, B. Eades, C. D. Abaya, A. Strayer, D. Nix, R. A. Swift
Journal: Journal of Clinical Oncology (2009)

e19508 Background: Nonclinical studies have demonstrated that histone deacetylase inhibitors (HDACi) significantly reduce the growth of MM cells and enhance cytotoxicity of the proteasome inhibitor bortezomib (Velcade). Romidepsin, a pan-HDACi, has previously shown activity for patients (pts) with relapsed or refractory MM when administered as a 4-hr infusion in combination with dexamethasone and bortezomib. Methods: This open-label, multi-center, phase II study (GPI-08–0006) was initiated to evaluate the activity and safety of a 1-hr infusion of romidepsin in combination with bortezomib for MM pts with relapsed or refractory disease and to evaluate the safety and single dose pharmacokinetics (PK)/pharmacodynamics of romidepsin in the first 5 pts. Pts received 10 mg/m 2 romidepsin on days 1, 8 and 15 and 1.0 mg/m 2 bortezomib on days 1, 4, 8 and 11 of a 28-day cycle. PK sampling and triplicate ECGs were performed at 0, 0.25, 0.5, 1, 2, 3, 4, 6 and 24 hrs after initiation of the first 1-hr infusion of romidepsin. Results: To date, 5 pts have been enrolled (median age 68 [range, 65–72]) 2 pts who relapsed from recent bortezomib-containing regimens experienced minimal responses after 2 cycles. 2 pts have experienced grade 3 thrombocytopenia. No pt had a QTcF value of &gt;480 ms the mean change in QTcF from baseline to C max was 4.2 ms (-10 to 13). Values for PK parameters are included in the table . When compared with data from pts who were treated with a 4-hr infusion of 14 mg/m 2 , the C max of the 1-hr infusion of romidepsin 10 mg/m 2 was ∼ 20% higher and exposure (AUC 0–24hr ) was reduced by 70%. Conclusions: Preliminary data suggest that the 1-hr infusion of romidepsin combined with bortezomib is active for pts with MM relapsed or refractory to bortezomib. Based on the initial incidence of grade 3 thrombocytopenia and PK data, additional pts are being treated on the same schedule but with a reduced dose of romidepsin (8 mg/m 2 ). This study continues to enroll pts. [Table: see text] [Table: see text]
Absence of Chromosomal Abnormalities Corresponds to Better Survival in Adult Ph-Negative ACUTE Lymphoblastic Leukemia – Results of the Russian ACUTE Lymphoblastic Leukemia (RALL) Study Group.
Authors: Elena Parovichnikova, Julia R Davidyan, Galina A Kliasova, Andrey N Sokolov, Vera V Troitskaya, Sergey M. Kulikov, Sergey N Bondarenko, Olga Yu Baranova, Alfia Nizametdinova, Tatyana S Kaporskaya, Olga S Samoilova, Valeriy Lapin, Valeriy G Savchenko
Journal: Blood (2012)
Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus with Mitoxantrone, Etoposide, and Cytarabine Chemotherapy.
Authors: Alexander E Perl, Kasner Margaret, Shank Doris, Selina Luger, Martin Carroll
Journal: Blood (2009)
A phase II study to evaluate the feasibility of bi-weekly docetaxel followed by bi-weekly doxorubicin and cyclophosphamide as adjuvant therapy for operable breast cancer (T-AC)
Authors: R. Lambert-Falls, M. Ackerman, G. T. Jones, R. Smith
Journal: Journal of Clinical Oncology (2004)

850 Background: Recent literature has supported dose dense therapy in the treatment of adjuvant breast cancer. This study sequences docetaxel(T) followed by doxorubicin(A) and cyclophosphamide(C). Docetaxel has shown to be superior to paclitaxel (P) as recently presented. This design demonstrates the feasibility of the most effective drugs, while minimizing toxicity. Methods: T-AC is an open label phase II trial sequencing docetaxel (100mg/m2) at 14 day intervals over 4 cycles followed by doxorubicin (60mg/m2) + cyclophosphamide (600mg/m2) at 14 day intervals over 4 cycles, for a total of 8 cycles with a 3 week break between drugs. Patients are supported with prophylactic G-CSF starting on day 2 of each cycle. Results: Seventeen of the 32 planned patients (pts.) have been enrolled. The first patient began therapy on 7/15/03. Currently, 3 patients have completed all 8 cycles, 8 have completed at least 4 cycles, and 6 have completed fewer than 4 cycles. The following Grade 3 and 4 toxicities have been experienced: 6 [Leukopenia]; 6 [Neutropenia]; 2 [Hand/Foot Syndrome]; 1 [Elevated ALT]; 1 [Elevated AST]; 1 [Infection with Neutropenia]. The table below shows the incidence of these Grade 3 and 4 Toxicities. Conclusions: One patient was removed from study due to progressive disease and accounts for two of the G4 toxicities and one of the G3 toxicities reported. Another patient was removed from study due to unresolved hand/foot syndrome and this is one of the G3 toxicities. The use of dose dense docetaxel followed by dose dense cyclophosphamide and doxorubicin in the adjuvant setting is feasible with acceptable toxicity based on the enrolled patient population. No significant financial relationships to disclose.
Impact of mutational status and other prognostic factors on survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.
Authors: Julien Domont, Sylvie Chabaud, Isabelle Ray Coquard, Binh Bui, Antoine Adenis, Maria Rios, François Bertucci, Florence Duffaud, Didier Cupissol, Christine Chevreau, Emmanuelle Bompas, Jean-François Emile, Jean-Michel Coindre, Jean-Yves Blay, Axel Le Cesne
Journal: Journal of Clinical Oncology (2013)

10548 Background: Factors predicting progression free survival (PFS) and overall survival (OS) of patients (pts) with advanced GIST treated with 400 mg daily dose IM were investigated. As mutational status was a secondary objective of the BFR14 study, we wanted to evaluate the added value of these genomic profiles to conventional clinical prognostic factors. Methods: 434 pts were included in this prospective multicenter trial from June 2002 to July 2009. Prognostic factors for survival were investigated in the cohort where the mutational status was available. A multivariate Cox model including baseline characteristics statistically significant in univariate were included in a backward procedure to identify independent prognostic factors for PFS then OS. Results: Mutational analysis were available in 322 pts. Material was insufficient in 55 cases (12.5%), incomplete results were obtained in 39 pts (9%). There were 196 KIT genetic alterations (exon 11: 173 pts, exon 9: 22 pts, exon 17: 1 pt), 6 GIST with a PDGFRA mutations and 26 GIST WT. The analysis of prognostic factors was performed in all mutated and non-mutated GIST (221 pts) except for pts with a KIT exon 17 and PDGFRa mutation. As of January 2013, median follow-up was 73 months (m) (CI95%:63; 86), 147 progressions (67%) were notified and 84 deaths (38%) occurred. The median PFS and OS were 12.3 m (CI95%: 2.1;32.7) and 54.9 m (CI95%:16.5;83.8) for WT GIST, 12.6m (CI95%: 6.1;30.8) and 55m (CI95%:33.5;83.0) for KIT exon 9 and 39.4m (CI95%: 31.4;54.4) and not reached for KIT exon 11, respectively. An initial low tumour volume, gender (female), and CD34 positivity were the three independent prognostic factors of a higher PFS. A higher OS was independently predicted by PS, low neutrophil counts, KIT exon 11 alterations, normal lymphocyte count, lower tumor size and female’s gender. Conclusions: GIST pts harboring a KIT exon 11 mutations have the better outcome but the mutational status is not the only prognostic factor influencing the outcome of pts. The clinical (gender, PS, tumor size) and biological characteristics (lymphocytes and neutrophil counts) remain critical for OS.
ULTRASOUND ACCELERATED CATHETER DIRECTED LYTIC THERAPY FOR MANAGEMENT OF PULMONARY EMBOLISM: IMPACT OF PROCEDURAL TIMING ON ECHOCARDIOGRAPHIC OUTCOMES AND SAFETY
Authors: Elias A. Iliadis, Nayan Desai, John Trujillo, Xin Zhang, Simon Topalian, Brian Corbett, Janah Aji
Journal: Journal of the American College of Cardiology (2017)
LONG-TERM THERAPY WITH ELAMIPRETIDE NORMALIZES ACTIVATION OF THE MITOCHONDRIAL SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (MSTAT3) IN OF LEFT VENTRICULAR MYOCARDIUM OF DOGS WITH CHRONIC HEART FAILURE
Authors: Ramesh C. Gupta, Vinita Singh-Gupta, Hani N. Sabbah
Journal: Journal of the American College of Cardiology (2017)
SMOKING AS A KEY PREDICTOR OF CAD AMONG ASYMPTOMATIC AND EXTREMELY LOW CORONARY ARTERY CALCIUM SCORE PATIENTS
Authors: Hyeon Ju Jeong, Hyung-Bok Park, Hyun-Jin Kim, Yong-Sung Seo, Yoon-Hyeong Cho, Tae-Young Choi, Eui-Seock Hwang, Deok-Kyu Cho
Journal: Journal of the American College of Cardiology (2017)
Ritonavir Based Highly Active Retroviral Therapy (HAART) Correlates with Early Neurotoxicity When Combined with ABVD Treated HIV Associated Hodgkin Lymphoma but Not Non-Hodgkin Lymphoma. A Retrospective Study.
Authors: Paul G. Rubinstein, Tareq Braik, Shivi Jain, Jennifer Orsi, Shweta Gupta, Gail Itokazu, Margaret Telfer, Muhammed Irfan, Audrey French
Journal: Blood (2010)
Metformin (met) use and outcome of sunitinib (Su) treatment (tx) in diabetic patients (pts) with metastatic renal cell carcinoma (mRCC).
Authors: Daniel Keizman, Maya Ish-Shalom, Avivit Peer, Adi Chish, Avishay Sella, Maya Gottfried, Hans J. Hammers, Mario A. Eisenberger, Victoria J. Sinibaldi, Victoria Neiman, Eli Rosenbaum, David Sarid, Eliahu Gez, Wilmosh Mermershtain, Keren Rouvinov, Rony Weitzen, Rony Weitzen, Raanan Berger, Michael Anthony Carducci
Journal: Journal of Clinical Oncology (2015)

e15618 Background: Su is a standard tx for mRCC. Pre-clinical and clinical studies in several cancer types suggest that the antidiabetic agent Met has antitumor activity. Met may negatively regulate mTOR activity. Its effect on the outcome of targeted therapies in mRCC is poorly defined. We analyzed the effect of Met use on the outcome sunitinib tx in diabetic pts with mRCC. Methods: We performed a retrospective study of an unselected cohort of diabetic pts with mRCC, who were treated with Su in 7 centers across 2 countries. Pts were divided into 2 groups: (1) Met users and (2) Met naive. The effect of Met use on response rate (RR), progression free survival (PFS) and overall survival (OS), was tested with adjustment of other known confounding risk factors using a chisquare test and partial likelihood test from cox model. Furthermore, univariate and multivariate analyses of association between clinicopathologic factors and Met use, and outcome were performed using the entire pt cohort. Results: Between 2004-2014, 108 diabetic pts with mRCC were treated with sunitinib. There were 52 Met users (group 1) and 56 nonusers (group 2). The groups were balanced regarding the following clinicopathologic factors: age, gender, HENG risk, past nephrectomy, mRCC histology, ≥ 2 metastatic sites, lung/liver/bone metastasis, prior targeted tx, smoking status, use of angiotensin system inhibitors (ASIs), pre-tx neutrophil to lymphocyte ratio (NLR) > 3, sunitinib induced hypertension (HTN), and su dose reduction/tx interruption. Clinical benefit (partial response + stable disease) in group 1 vs 2 was 96% vs 84%, while 4% vs 16% had disease progression within the first 3 months of tx (p = 0.054). Median PFS was 15 vs 11.5 months (p = 0.1). Median OS was 32 vs 21 months (p = 0.001). In multivariate analyses of the entire pt cohort (n = 108), factors associated with PFS were active smoking (HR = 2.7, p < 0.0001) and pre-tx NLR > 3 (HR 1.8, p = 0.012). Factors associated with OS were Met use (HR 0.2, p < 0.0001), HENG risk (HR 3.3, p = 0.008), active smoking (HR = 2.9, p < 0.0001), liver metastases (HR 1.8, p = 0.004), and pre-tx NLR > 3 (HR 3.3, p < 0.0001). Conclusions: Met use may improve the OS of diabetic pts with mRCC that are treated with sunitinib.
Should crizotinib be dosed to sinus bradycardia (SB) (HR &lt; 55)? A single institution, retrospective analysis of heart rate (HR) changes and tumor response in crizotinib treated NSCLC patients.
Authors: Wilson P. Tong, Michele Azada, Sai-Hong Ignatius Ou
Journal: Journal of Clinical Oncology (2012)

e18140 Background: Crizotinib can result in SB as a part of its dose-dependent pharmacodynamic property. We analyzed the correlation between SB and tumor response in ALK or MET+ NSCLC patients (pts). Methods: Single institution retrospectively analysis of SB incidence (HR &lt; 55) of ALK or MET+ NSCLC patients enrolled in 2 phase II crizotinib trials. Comparison performed between pt characteristics, HR changes, treatment duration, tumor response and shrinkage according to SB status. Results: 42 ALK or MET+ NSCLC pts (30 from A8081001, 12 from PROFILE1005) rx’d with crizotinib 250 mg po bid were analyzed. 90% of pts had a HR decrease of &gt; 10 beats per minutes (bpm). 19 (45%) patients developed at least 1 SB episode at anytime during crizotinib treatment including 8 (19%) pts with profound SB (HR =&lt; 45). All pts with SB were asymptomatic. There was no difference in the median age of diagnosis between pts (57.6 yrs [SB] vs. 49.7 yrs [no SB]; p = 0.073) by SB status. Median time to SB was 3 wks (mean: 7.2 wks, range 2-32 wks). There was significant difference in the mean pre-Rx baseline HR by SB status (74.5 bpm [SB] vs. 92.6 bpm [no SB]; p = 0.005), Rx duration (57.3 wks [SB] vs. 33.3 wks [no SB]; p = 0.021). The average maximum HR decrease (MHRD) from baseline for all pts were 26.3 bpm. There was no significant difference in the mean MHRD from baseline according to SB status (28.2 bpm [SB] vs. 24.7 bpm [no SB]; p = 0.598). 68% (13/19) of SB pts compared to 35% (8/23) of pts without SB achieved a CR/PR (p = 0.030). The mean maximum decrease in tumor measurements (MDTM) (RECIST) was 46.2% for pts with SB compared to 32.0% for pts without SB (p = 0.095). There was no difference in the mean MDTM in pts who achieved CR/PR without SB (62.5%) and with SB (63.5%) (p = 0.913) nor the mean response duration (RD) in CR/PR pts by SB status (43.3 wks [SB] vs. 51.5 wks [no SB]; p = 0.426). Conclusions: HR decrease is common in pts treated with crizotinib. Pts who developed asymptomatic SB had significantly lower pre-Rx baseline HR, longer Rx duration, higher response rates. However there was no difference in the mean MDTM or RD between pts who achieved CR/PR by SB status.